Apologies to cats.

No, it doesn't mean antivirals don't work.

It means they work well and that Pharma wants them to be sold to
people or governments with lots of money to pay their rapist prices.
If people or governments won't pay their price, then people with HIV
can simply develop AIDS and die by the millions for all they care.

Or any other disease.
George M. Carter

**
Pharma  Salaries. The high cost of research
Source: AFL-CIO Executive Paywatch

Henry A.  McKinnell
Chairman and CEO
Pfizer Inc.  
In 2004, Henry  A. McKinnell raked in $28,925,241 in total
compensation including stock option  grants from Pfizer Inc.. And
Henry A. McKinnell has another $15,096,811 in unexercised stock
options from previous years.  

John C.  Martin
President and CEO
Gilead Sciences  
In 2004, John C. Martin raked in $18,223,931 in total  compensation
including stock option grants from Gilead Sciences. From previous
years' stock option grants, the Gilead Sciences executive  cashed out
$13,213,769 in stock option exercises. And John  C. Martin has another
$113,984,508 in unexercised stock options from previous  years.  

Henri A.  Termeer
CEO
Genzyme Corp.  
In 2003, Henri A. Termeer raked in $17,154,464 in total  compensation
including stock option grants from Genzyme Corp. From previous years'
stock option grants, the Genzyme Corp. executive  cashed out
$16,202,363 in stock option exercises. And Henri  A. Termeer has
another $58,964,049 in unexercised stock options from previous  years.

Sidney  Taurel
Chairman President and CEO
Lilly (Eli) & Co.  
In 2004, Sidney Taurel raked in $15,511,784 in total  compensation
including stock option grants from Lilly (Eli) & Co. From previous
years' stock option grants, the Lilly (Eli)  & Co. executive cashed
out $4,091,400 in stock option exercises. And Sidney Taurel has
another $13,119,533 in unexercised  stock options from previous years.

David M.  Mott
Vice Chairman President and CEO
MedImmune Inc.  
In 2003, David M. Mott raked in $15,330,493 in total  compensation
including stock option grants from MedImmune Inc. And David M. Mott
has another $10,936,529 in unexercised stock options  from previous
years.  

Robert  Essner
Chairman President and CEO
Wyeth  
In 2004, Robert Essner raked in $11,764,945 in total  compensation
including stock option grants from Wyeth. And  Robert Essner has
another $4,278,990 in unexercised stock options from previous  years.

Miles D.  White
Chairman and CEO
Abbott Labs  
In 2004, Miles D. White raked in $11,298,642 in total  compensation
including stock option grants from Abbott Labs. And Miles D. White has
another $21,450,196 in unexercised stock options  from previous years.

Kevin W.  Sharer
Chairman CEO and President
Amgen  
In 2004, Kevin W. Sharer raked in $11,031,845 in total  compensation
including stock option grants from Amgen. From  previous years' stock
option grants, the Amgen executive cashed out $140,757 in  stock
option exercises. And Kevin W. Sharer has another  $14,392,208 in
unexercised stock options from previous years.  

Raymond V.  Gilmartin
Chairman President and CEO
Merck & Co.  
In 2004, Raymond V. Gilmartin raked in $10,568,702 in total
compensation including stock option grants from Merck & Co. From
previous years' stock option grants, the Merck & Co. executive  cashed
out $34,802,748 in stock option exercises. And  Raymond V. Gilmartin
has another $4,982,632 in unexercised stock options from  previous
years.  

Robert J.  Coury
Vice Chairman and CEO
Mylan Laboratories  
In 2004, Robert J. Coury raked in $9,277,603 in total  compensation
including stock option grants from Mylan Laboratories. And Robert J.
Coury has another $11,984,966 in unexercised stock options  from
previous years.  

Howard  Solomon
Chairman and CEO
Forest Laboratories  
In 2004, Howard Solomon raked in $8,996,921 in total  compensation
including stock option grants from Forest Laboratories. From previous
years' stock option grants, the Forest  Laboratories executive cashed
out $90,546,050 in stock option exercises. And Howard Solomon has
another $318,459,960 in unexercised  stock options from previous
years.  

P R.  Dolan
Chairman and CEO
Bristol-Myers Squibb  
In 2004, P R. Dolan raked in $8,796,679 in total compensation
including stock option grants from Bristol-Myers Squibb. And  P R.
Dolan has another $1,471,145 in unexercised stock options from
previous  years  

Robert L.  Parkinson
Chairman and CEO
Baxter International Inc.  
In 2004, Robert L. Parkinson raked in $8,757,902 in total
compensation including stock option grants from Baxter International
Inc. And Robert L. Parkinson has another $1,833,000 in  unexercised
stock options from previous years.  

Jonathan W.  Ayers
President and CEO
IDEXX Laboratories  
In 2004, Jonathan W. Ayers raked in $8,094,317 in total  compensation
including stock option grants from IDEXX Laboratories. From previous
years' stock option grants, the IDEXX Laboratories  executive cashed
out $102,771 in stock option exercises. And  Jonathan W. Ayers has
another $14,719,211 in unexercised
stock options from  previous years.